Could a vaccine train Kids' immune systems to fight brain cancer?
NCT ID NCT04978727
First seen Mar 09, 2026 · Last updated Jun 19, 2026 · Updated 15 times
Summary
This early-phase trial tests a vaccine called SurVaxM in 35 children and young adults with brain tumors that have come back or are hard to treat. The vaccine is designed to teach the immune system to find and destroy cancer cells that carry a protein called survivin. Participants receive the vaccine as a shot under the skin every two weeks for six weeks, then every eight weeks for up to two years if the disease is stable. The main goal is to check safety and see how the immune system responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPENDYMOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611, United States
-
Children's Healthcare of Atlanta
Atlanta, Georgia, 30322, United States
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90026, United States
-
Children's National
Washington D.C., District of Columbia, 20010, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
Lucile Packard Children's Hospital at Stanford University Medical Center
Palo Alto, California, 94304, United States
-
Memorial Sloan Kettering
New York, New York, 10065, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
-
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15224, United States
-
University of Florida
Gainesville, Florida, 32608, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SurVaxM (a cancer vaccine) mixed with Montanide ISA 51 and given with sargramostim
What this could lead to
If it works, this could point toward a new way to control tumor growth and delay recurrence in children with certain brain cancers.
What could go wrong
This is a very early (Phase 1) pilot study with only 35 participants, so it is primarily testing safety. The vaccine may not shrink tumors or improve survival, and there is a risk of side effects or pseudoprogression (temporary swelling that mimics tumor growth).
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.